Allen Investment Management LLC Increases Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Allen Investment Management LLC increased its stake in Eli Lilly by 29.3% in the fourth quarter, buying 1,936 more shares and bringing its holdings to 8,541 shares worth about $9.18 million.
• Eli Lilly posted strong quarterly results, with EPS of $8.55 beating estimates and revenue of $19.8 billion topping expectations, while revenue surged 55.5% year over year. The company also raised its FY 2026 EPS guidance to 35.5–37.0.
• The company continues to attract bullish analyst sentiment, with a Moderate Buy consensus and an average price target of $1,227. At the same time, Lilly faces some headwinds from recent stock pullbacks and ongoing GLP-1 competition, especially from Novo Nordisk.

Allen Investment Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 29.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,541 shares of the company's stock after buying an additional 1,936 shares during the quarter. Allen Investment Management LLC's holdings in Eli Lilly and Company were worth $9,178,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cidel Asset Management Inc. grew its holdings in shares of Eli Lilly and Company by 26.5% during the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after purchasing an additional 5,591 shares during the period. Spire Wealth Management raised its holdings in Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company's stock valued at $29,789,000 after buying an additional 592 shares during the period. Coldstream Capital Management Inc. lifted its position in Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock valued at $32,365,000 after buying an additional 8,659 shares in the last quarter. Farther Finance Advisors LLC lifted its position in Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company's stock valued at $33,471,000 after buying an additional 7,338 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its stake in Eli Lilly and Company by 3.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company's stock worth $126,022,000 after buying an additional 5,595 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,079.96 on Tuesday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,149.10. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The firm has a market cap of $1.02 trillion, a price-to-earnings ratio of 38.36, a PEG ratio of 1.21 and a beta of 0.53. The stock has a 50 day moving average of $959.18 and a 200-day moving average of $1,010.74.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period in the prior year, the company posted $3.34 EPS. The business's revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported strong Phase 3 data for Retevmo (selpercatinib), showing an 83% reduction in the risk of disease recurrence or death in early-stage RET fusion-positive lung cancer, a result that could support a broader label and future revenue growth. Article Title
• Positive Sentiment: The company also signed new licensing and collaboration deals with Hanmi and Haisco, extending its innovation pipeline and signaling continued deal-making momentum in Asia. Article Title
• Positive Sentiment: Camurus said Lilly exercised an option in their cardiometabolic drug collaboration, extending another pipeline partnership and adding to investor confidence in Lilly’s long-term growth strategy. Article Title
• Positive Sentiment: Market commentary remained bullish after CEO David Ricks’ remarks about Lilly’s hot product lineup, while social sentiment and analyst coverage continued to highlight the company as one of the market’s leading growth names. Article Title
• Neutral Sentiment: Some articles framed Lilly as one of the top stocks to watch, but these pieces were mostly commentary rather than new company-specific catalysts. Article Title
• Negative Sentiment: Despite the positive news, LLY has been trading lower recently, and some market attention appears to reflect profit-taking after a strong run and valuation concerns rather than a deterioration in fundamentals. Article Title
• Negative Sentiment: Competitive pressure in the GLP-1 market remains a risk, as Novo Nordisk’s oral Wegovy pill is still outperforming Lilly’s rival tablet, even though growth is slowing. Article Title

Analysts Set New Price Targets

A number of equities analysts have recently commented on LLY shares. Wolfe Research reissued an "outperform" rating and issued a $1,350.00 target price on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Freedom Capital raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 10th. Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a research note on Tuesday, February 10th. Scotiabank reissued an "outperform" rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, Daiwa Securities Group upped their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a "buy" rating in a report on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $1,227.00.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.